

## ASYMMETRIC SYNTHESIS OF $\beta$ -LACTAMS AND *N*-BENZOYL-3-PHENYLISOSERINES VIA THE STAUDINGER REACTION


Gunda I. Georg,\* Peter M. Mashava,<sup>1a</sup> Eyüp Akgün,<sup>1b</sup> and Mark W. Milstead<sup>1c</sup>

*Department of Medicinal Chemistry  
University of Kansas, Lawrence, KS 66045-2506 U.S.A.*

**Abstract:** Reaction of benzaldimine **5** derived from 2,3,4,6-tetra-O-acetyl- $\beta$ -D-galactoseamine with acid chloride **6** yields *cis*  $\beta$ -lactam **7** as a single diastereoisomer. Hydrolysis of  $\beta$ -lactam **7** followed by *N*-benzoylation provides access toward *N*-benzoyl-(2*S*,3*R*)-3-phenylisoserine **9**. *N*-Benzoyl-3-phenylisoserines are important building blocks for the semi-synthesis of the anti-cancer agent taxol.



Several research groups have by now independently recognized<sup>2,3,4</sup> that optically active 3-hydroxy-4-phenyl-2-azetidinone **1** is an excellent precursor for the synthesis of *N*-benzoyl-(2*R*,3*S*)-3-phenylisoserine **2** and related  $\alpha$ -hydroxy  $\beta$ -amino acids (Scheme 1).

Scheme 1



*N*-Benzoyl-3-phenylisoserine **2** can be utilized for the semi-synthesis of the potent anti-tumor agent taxol. Taxol **3**, a complex diterpene which has been isolated in small quantities from the bark of *Taxus brevifolia*, is currently considered the most exciting lead in cancer chemotherapy.<sup>5</sup> Taxol is in phase II clinical trials in the United States. Activity against cisplatin refractory advanced ovarian cancer has been established.<sup>5</sup> Widespread concern has been voiced that the very slow growing trees may be threatened by extinction should taxol prove to be highly effective in cancer chemotherapy.<sup>6</sup>

A recent report has detailed that a more readily available taxol precursor can be isolated from the needles of *Taxus baccata*.<sup>6</sup> Extraction of the fresh needles yields 10-deacetylbaccatin III **4** in up to 1 g/kg. Of note is that the harvest does not threaten the survival of the species. 10-Deacetylbaccatin III **4** has been converted to taxol *via* coupling<sup>6</sup> to *N*-benzoyl-3-phenylisoserine **2** and a derivative of **1**.<sup>3</sup> SAR studies of derivatives of **3** have revealed that the *N*-benzoyl-3-phenylisoserine side chain at C-13 of the taxol molecule is of crucial importance for the antitumor activity of taxol.<sup>7</sup> Asymmetric syntheses of **2** have been achieved *via* the Sharpless epoxidation,<sup>8</sup> the Sharpless dihydroxylation<sup>9</sup> reaction, and the ester enolate imine condensation.<sup>2</sup> Other approaches to obtain optically active **2** involve the separation<sup>3</sup> of diastereoisomers derived from **1** and the resolution of a derivative of **2** by enzymatic hydrolysis.<sup>10</sup>

Taxol **3**10-Deacetylbaccatin III **4**


We now wish to report on our preliminary studies towards the asymmetric synthesis of  $\beta$ -lactams and phenylisoserines of type **1** and **2** *via* the Staudinger reaction<sup>11,12</sup> (Scheme 2). Reaction between galactose imine **5**<sup>13</sup> and acid chloride **6** in the presence of triethylamine gave a single diastereoisomer **7** (as shown by NMR) with *cis* stereochemistry at the  $\beta$ -lactam ring in 75% yield. Hydrolysis of **7** with hydrochloric acid (6*N*) in methanol followed by benzylation of the crude reaction product gave the *N*-benzoyl-3-phenylisoserine derivative **8** in 84% yield. Oxidative dearylation<sup>14</sup> of **8** with ammonium cerium (IV) nitrate (CAN) produced phenylisoserine methyl ester **9** ( $[\alpha]_D + 48.3^\circ$ , *c* 0.575, CHCl<sub>3</sub>) in 95% yield.<sup>15</sup>

Comparison of the optical rotation of **9** with published data<sup>8</sup> revealed that we had obtained an optically pure sample of the 2*S*,3*R* phenylisoserine methyl ester **9**. However, phenylisoserine **9** is enantiomeric to the desired phenylisoserine **2**, necessary for the conversion to taxol. We are therefore planning to utilize imines<sup>13</sup> derived from D-arabinose and L-fucose toward the synthesis of the desired phenylisoserine isomer **2** with 2*R*, 3*S* stereochemistry.

It should be pointed out that  $\beta$ -lactam **7** possesses the correct absolute stereochemistry at the  $\beta$ -lactam ring as necessary for the synthesis of  $\beta$ -lactam antibiotics.<sup>16</sup> Preliminary results<sup>17</sup> in our laboratories have indicated that the sugar moiety of **7** can be removed hydrolytically while keeping the  $\beta$ -lactam ring system intact.

Thus, the Staudinger reaction involving optically active imines of type **5** should be a very promising approach not only for the synthesis of optically active phenylisoserines but also for the synthesis of optically active precursors for the synthesis of  $\beta$ -lactam antibiotics. These studies are currently underway in our laboratories.

Scheme 2



**Acknowledgements:** Financial assistance from the National Institutes of Health (GM 42260 and CA 52790), the Biomedical Research Fund (RR 5606) at the University of Kansas, and the University of Zimbabwe Research Board for a travel grant to P. M. M. is acknowledged.

## REFERENCES AND NOTES

- (1) (a) African-American Institute (New York) Post-Graduate Award recipient. Visiting Scientist on leave from the University of Zimbabwe, Department of Science and Mathematics Education, Harare, Zimbabwe, Africa. (b) Recipient of an award from the Wesley Foundation Scholar Program in Cancer Research (Wichita, KS). (c) National Institutes of Health predoctoral trainee (GM 07775).
- (2) Ojima, I.; Habus, I.; Zhao, M.; Georg, G. I.; Jayasinghe, L. R. *J. Org. Chem.* **1991**, *56*, 1681.
- (3) Holton, R. A.; Liu, J. H.; Gentile, L. N. (personal communication).
- (4) Palomo, C.; Aizpurua, J. M.; Lopez, M. C.; Aurrekoetxea, N.; Oiarbide, M. *Tetrahedron Lett.* **1990**, *31*, 6425.
- (5) For recent reviews see: Rowinsky, E. K.; Cazenave, L. A.; Donehower, R. C. *J. Natl. Cancer Inst.* **1990**, *82*, 1247. Workshop on Taxol and Taxus: *Current and Future Perspectives*; June 1990; Division of Cancer Treatment, NCI, Bethesda.
- (6) Denis, J. N.; Greene, A. E.; Guenard, D.; Gueritte-Voegelein, F.; Mangatal, L.; Potier, P. *J. Am. Chem. Soc.* **1988**, *110*, 5917.
- (7) For a recent review see: Kingston, D. A.; Samaranayake, G.; Ivey, C. A. *J. Nat. Prod.* **1990**, *53*, 1.
- (8) Denis, J. N.; Greene, A. E.; Serra, A. A.; Luche, M.-J. *J. Org. Chem.* **1986**, *51*, 46.
- (9) Denis, J. N.; Correa, A.; Greene, A. E. *J. Org. Chem.* **1990**, *55*, 1957.
- (10) Hönig, H.; Seuffer-Wasserthal, P.; Weber, H. *Tetrahedron* **1990**, *46*, 3841.
- (11) For leading references regarding asymmetric versions of the Staudinger reaction see: Cooper, R. D. G.; Daugherty, B. W.; Boyd, D. B. *Pure and Appl. Chem.* **1987**, *59*, 485. Kobayashi, Y.; Takemoto, Y.; Ito, Y.; Terashima, S. *Tetrahedron Lett.* **1990**, *31*, 3031.
- (12) For the utilization of carbohydrates as chiral auxiliaries in the Staudinger reaction see: Barton, D. H. R.; Gateau-Olesker, A.; Anaya-Mateos, J.; Cleophax, J.; Gero, S. D.; Chiaroni, A.; Riche, C. *J. Chem. Soc., Perkin. Trans. 1* **1990**, 3211. Bose, A. K.; Kaluza, Z.; Urbanczyk-Lipkowska, Z.; Manhas, M. S. 199th National Meeting of the American Chemical Society, Boston, Massachusetts; American Chemical Society: Washington, DC, 1990; ORGN 370. Borer, B.C.; Balogh, D.W. *Tetrahedron Lett.* **1991**, *32*, 1039.
- (13) For a review on the use of galactose imines in asymmetric synthesis see: Kunz, H. In *Selectivities in Lewis Acid Promoted Reactions*; Schinzer, D., Ed.; Kluwer Academic: Dordrecht, 1989; pp 189-202 and references cited therein. See also: Laschat, S.; Kunz, H. *Synlett* **1990**, 629.
- (14) Georg, G. I.; Kant, J.; Gill, H. *J. Am. Chem. Soc.* **1987**, *109*, 1129.
- (15) All compounds exhibited spectroscopic data in agreement with their structural assignments. The addition of the acid chloride **6** to imine **5** was performed at 0 °C. Compounds **7**, **8**, and **9** were purified by column chromatography.  $\beta$ -Lactam **7** could not easily be separated from the starting imine and was therefore subjected to hydrolysis containing a small impurity of imine **5**.
- (16) Mitscher, L. A.; Georg, G. I.; Motohashi, N. In *CRC Handbook of Stereoisomers. Therapeutic Drugs*; Smith, D.F., Ed.; CRC: Boca Raton, 1989; Vol. II, pp 199-234.
- (17) Georg, G. I.; Mashava, P. M.; Akgün, E. (unpublished results).

(Received in USA 20 March 1991)